CKCheng-Hao Ko

Cheng-Hao Ko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheng-Hao Ko has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SpecCal-Transfer: Physics-Guided Augmentation-Based Spectral Calibration Transfer for Reagent-Strip Urinalysis

    by Ashenafi Belihu Tadesse, Cheng-Hao Ko

    Calibration transfer for portable reagent-strip spectroscopy is challenged by optical and instrumental variation. SpecCal-Transfer examines physics-guided spectral augmentation using 288 SpectroChip spectra representing 12 reagent-strip response classes, eight nominal control-mixture fractions, and three repeated acquisitions. Simulated gain, baseline drift, wavelength displacement, noise, spectral smoothing, missing-band corruption, and combined changes were used to evaluate source-only regression, shift-aware augmentation, neural correlation alignment (CORAL), maximum mean discrepancy (MMD), conventional standardization, and simulated limited-reference adaptation. In an extremely randomized trees (ExtraTrees) evaluation, physics-guided training reduced moderate wavelength-shift root-mean-square error (RMSE) from 0.1476 to 0.1233 (16.53% mean paired reduction) and combined-shift RMSE from 0.1504 to 0.1232 (18.17%). An independent training-size control yielded 0.1240 with expanded augmentation versus 0.1502 without augmentation under moderate wavelength shifts; size-matched gains were smaller. Under wavelength perturbations at previously withheld interior fractions, physics-guided augmentation achieved RMSE 0.1612 versus 0.1661 for a magnitude-matched generic control. Neural alignment and simulated recalibration had condition-dependent effects. These results establish computational robustness under specified measurement mechanisms, not experimental inter-device transfer or analyte-specific concentration accuracy.

  • Open Access

    Correction: High-sensitivity SpectroChip-integrated LFIA platform for rapid point-of-care quantification of cardiovascular biomarkers

    by Cheng-Hao Ko, Wei-Yi Kong

    Correction for ‘High-sensitivity SpectroChip-integrated LFIA platform for rapid point-of-care quantification of cardiovascular biomarkers’ by Cheng-Hao Ko et al. , Analyst , 2025, 150 , 4930–4947, https://doi.org/10.1039/D5AN00846H.

  • High-sensitivity SpectroChip-integrated LFIA platform for rapid point-of-care quantification of cardiovascular biomarkers

    by Cheng-Hao Ko, Wei-Yi Kong

    Timely and precise measurement of cardiovascular biomarkers is crucial for early diagnosis and effective management of heart disease. This study evaluates THE ONE InstantCare device, a point-of-care (POC) platform that integrates a SpectroChip technology with gold nanoparticles (AuNPs)-conjugated lateral flow immunoassays (LFIA). Using this platform, we quantified five clinically significant cardiovascular biomarkers: Troponin I (cTnI), Creatine Kinase Myocardial Band (CK-MB), N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), D-dimer, and C-reactive Protein (CRP). Standard curves were generated from serial dilutions of known concentrations spiked into fetal bovine serum (FBS). Spectral data were averaged across three replicates and preprocessed using baseline correction and noise reduction techniques. Relative absorbance (ΔA) was calculated by subtracting the absorbance at 680 nm (baseline) from that at 530 nm (peak), minimizing baseline interference and enhancing quantitative accuracy. The platform achieved limits of detection (LOD) as low as 0.0124 ng mL−1 (cTnI), 0.0342 ng mL−1 (CK-MB), 0.1422 ng mL−1 (NT-proBNP), 0.0213 ng L−1 (D-dimer), and 0.0304 ng L−1 (CRP) with R2 values above 0.98 for all calibration curves. Clinical validation using 47 patient serum samples showed strong agreement with the Abbott Alinity ci-series analyzer (R2 > 0.91, r > 0.95). Bland–Altman analysis confirmed consistency within 95% confidence intervals. These results highlight the potential of the proposed novel Point-of-Care (POC) system to deliver fast, reliable and affordable cardiovascular diagnostics in emergency care settings.


  • Open Access

    Portable SpectroChip-Based Immunoassay Platform for Rapid and Accurate Melamine Quantification in Urine Samples

    by Cheng-Hao Ko, Wei-Yi Kong, Abel Chernet Kabiso, Wei-Huai Chiu, Ashenafi Belihu Tadesse, Chitsung Hong, Chia-Fang Wu, Hung-Hsun Lin

    Growing concerns about the health risks of melamine adulteration in food products highlight the urgent need for reliable detection methods. However, the long-term effects of chronic low-level melamine exposure remain inadequately explored. This study introduces THE ONE InstantCare platform, a portable immunoassay analyzer integrating a SpectroChip-based spectral processing unit (SPU) with lateral flow immunoassay (LFIA) for sensitive and accurate quantification of melamine in human urine. This platform provides a cost-effective, rapid, and user-friendly point-of-care (POC) solution for melamine detection. Analytical evaluations across eight melamine concentrations (0–100 parts per billion, ppb) achieved a limit of detection (LOD) of 1.91 ppb. Validation with 24 human urine samples demonstrated strong concordance with liquid chromatography–mass spectrometry (LC-MS), yielding an intraclass correlation coefficient (ICC) of 0.9220, a Pearson correlation coefficient of 0.9389, and 95% agreement in Bland–Altman analysis. High reproducibility was observed, with an intraday coefficient of variation (CV) of 6.53% and acceptable interday CV values, while interference studies confirmed reliability in the presence of common biological substances. By delivering results in approximately 10 min, THE ONE InstantCare platform significantly reduces analysis time compared to LC-MS, which typically requires several hours. This novel platform enhances food safety surveillance and advances human health risk assessments, particularly for evaluating melamine-linked kidney damage. Its versatility and robust performance make it a promising tool for environmental monitoring and clinical diagnostics, enabling the detection of diverse biomarkers with high sensitivity and reproducibility.


  • Open Access

    Spectrochip-based Calibration Curve Modeling (CCM) for Rapid and Accurate Multiple Analytes Quantification in Urinalysis

    by Cheng-Hao Ko, Ashenafi Belihu Tadesse, Abel Chernet Kabiso


  • Open Access

    Using an ultra-compact optical system to improve lateral flow immunoassay results quantitatively

    by Wei-Huai Chiu, Wei-Yi Kong, Yuan-Hui Chueh, Jyun-Wei Wen, Ciao-Ming Tsai, Chitsung Hong, Pang-Yen Chen, Cheng-Hao Ko


  • Open Access

    A Faster, Novel Technique to Detect COVID-19 Neutralizing Antibodies

    by Wei-Huai Chiu, Wei-Yi Kong, Yu-Jang Su, Jyun-Wei Wen, Ciao-Ming Tsai, Chitsung Hong, Pang-Yen Chen, Cheng-Hao Ko

    The COVID-19 pandemic has spread globally in a short period of time. It is known that antibody (nAb) level can effectively predict vaccine efficacy, which leads to the exploration of vaccine trials for efficacy assessment. Thus, the current study aimed to develop a platform to quantify nAb levels faster, at lower cost, and with better efficiency. A total of 69 sera samples were collected for the research, 28 of which were from unvaccinated participants. The other 27 samples and the remaining 14 samples were from the participants who had received the first and second dose, respectively, of AZ vaccine 1 month before. With cPass assays (Genscript cPass nAb ELISA assay) used as a criterion standard and lateral flow immunoassay kit (Healgen Scientific – LFIA test kit) coupled with a spectrometer (LFIA+S) for checking each specimen, we aimed to detect the presence of neutralizing antibodies in sera and to confirm the relationship between the inhibition rate from cPass assays and the nAb index from the LFIA+S. Data analysis of the research were taken from the certified ELISA and LFIA+S, which indicated a high consistency (Pearson’s r=0.864; ICC=0.90138) between the 2 methods. The dataset demonstrated that LFIA+S was affordable, had a strong correlation with results of the cPass nAbs detection kit, and has potential clinical applications, with an exclusive feature that allows non-experts to use it with ease. It is believed that the proposed platform can be promoted in the near future.


  • Open Access

    Quantitative Spectrochip-Coupled Lateral Flow Immunoassay Demonstrates Clinical Potential for Overcoming Coronavirus Disease 2019 Pandemic Screening Challenges

    by Kai-Feng Hung, Chih-Hsing Hung, Chitsung Hong, Szu-Chia Chen, Yi-Chen Sun, Jyun-Wei Wen, Chao-Hung Kuo, Cheng-Hao Ko, Chao-Min Cheng

    As coronavirus disease 2019 (COVID-19) continues to spread around the world, the establishment of decentralized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) diagnostics and point-of-care testing is invaluable. While polymerase chain reaction (PCR) has been the gold standard for COVID-19 screening, serological assays detecting anti-SARS-CoV-2 antibodies in response to past and/or current infection remain vital tools. In particular, lateral flow immunoassay devices are easy to produce, scale, distribute, and use; however, they are unable to provide quantitative information. To enable quantitative analysis of lateral flow immunoassay device results, microgating technology was used to develop an innovative spectrochip that can be integrated into a portable, palm-sized device that was capable of capturing high-resolution reflectance spectrum data for quantitative immunoassay diagnostics. Using predefined spiked concentrations of recombinant anti-SARS-CoV-2 immunoglobulin G (IgG), this spectrochip-coupled immunoassay provided extraordinary sensitivity, with a detection limit as low as 186 pg/mL. Furthermore, this platform enabled the detection of anti-SARS-CoV-2 IgG in all PCR-confirmed patients as early as day 3 after symptom onset, including two patients whose spectrochip tests would be regarded as negative for COVID-19 using a direct visual read-out without spectral analysis. Therefore, the quantitative lateral flow immunoassay with an exceptionally low detection limit for SARS-CoV-2 is of value. An increase in the number of patients tested with this novel device may reveal its true clinical potential.


  • Open Access

    The Clinical Potential of Point-of-Care Quantitative Spectrochip Coupled with Lateral Flow Immunoassay during the COVID-19 Pandemic

    by Pang-Yen Chen, Cheng-Hao Ko, C. Jason Wang, I-Jen Wang

    Coronavirus disease (COVID-19) is a large-scale global public health challenge that still persists. A method that achieves the rapid quantitative detection of antibodies to assess the body’s immune response from a natural COVID-19 illness or the vaccines’ effects is urgently needed. In the present study, we integrated a newly designed spectrometer with COVID-19 test strip procedures; this augmentation provides the capacity for a lateral flow immunoassay (LFIA) to be quantitative. Optical interpretation of results by quantitative α index was undertaken, rather than visual qualification. It can be performed quickly in 5–10 min. We compared the developed product with several other serological IgM/IgG antibody reagents on the market by recruiting 111 participants with a suspected COVID-19 infection from March to May 2020 in a single hospital. Taking RT-PCR as the diagnostic gold standard, the quantitative spectral LIFA platform could detect all 12 COVID-19 patients correctly (100% sensitivity, 12/12). In contrast, the sensitivity for ACE Biolab alone is 91.67% (11/12), and for Biomedomics, it is 58.33% (7/12). Methods that use Nucleocapsid (N) + Spike (S) solid-phase antigen (i.e., ACE Biolab, TBG, and Spectrochip +ACE Biolab) perform better compared with those that use Nucleocapsid (Biomedomics) or Spike (ASK) alone. Concerning negative RT-PCR patients, all three antibody testing methods found positive cases. The optical-based platform exhibited the ability of the early detection of immunoglobulins of negative RT-PCR patients. There was an apparent trend of an elevation of IgM levels in the acute phase of infection, then the IgG levels rose again later. It exhibited the risk of a false-negative diagnosis of RT-PCR in COVID-19 testing. The significant detection ability of this new optical-based platform demonstrated clinical potential.